Chris Markoch

Chris Markoch

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

8 Coronavirus Stocks That Are Still Going Strong

As Americans begin to realize the novel coronavirus is becoming something we will be living with for some time, these coronavirus stocks remain good buys.

It’s Time to Get Serious About Inovio Pharmaceuticals

Due to the government's desire to develop multiple vaccine candidates and several intriguing catalysts, INO stock deserves serious consideration.

Novavax Stock Needs Solid Results Beyond Headlines

NVAX stock is one of the hottest biotech stocks in 2020. But it's time for the company to deliver results worthy of its price.

What Makes FuelCell Unique Is What Makes It a Risky Buy

Hydrogen fuel cells (HFCs) are trendy as renewable energy moves to center stage. But is there enough demand for HFC power plants to make FCEL stock a buy?

5 Sin Stocks to Gamble On

Sin stocks tend to perform well in good times and bad. However the unique nature of the novel coronavirus is rewarding some vices more than others.